Literature DB >> 23615402

6,7-Dimethoxy-3-(3-methoxyphenyl)isoquinolin-1-amine induces mitotic arrest and apoptotic cell death through the activation of spindle assembly checkpoint in human cervical cancer cells.

Kyung-Sook Chung1, Hye-Eun Choi, Ji-Sun Shin, Young-Wuk Cho, Jung-Hye Choi, Won-Jea Cho, Kyung-Tae Lee.   

Abstract

Previously, we reported that 6,7-dimethoxy-3-(3-methoxyphenyl)isoquinolin-1-amine (CWJ-082) has potent cytotoxic effects on various cancer cells, but the underlying molecular mechanism responsible was not determined. In the present study, CWJ-082 caused cervical cancer cell cycle arrest at the G2/M phase and subsequent caspase-dependent apoptosis. The mitotic arrest caused by CWJ-082 found to be due to increases in the activation of cyclin-dependent kinase 1/cyclin B1 complex and the phosphorylation of histone H3. In addition, CWJ-082 induced the phosphorylation of BubR1 and the association between mitotic arrest deficient 2 (Mad2) and cell division cycle protein 20. These findings suggested that CWJ-082 activated the mitotic spindle checkpoint. Furthermore, knockdown of the spindle checkpoint proteins BubR1 or Mad2 using specific small interfering RNAs significantly reduced CWJ-082-induced mitotic cell accumulation and apoptosis. In addition, CWJ-082 induced the appearance of spindle abnormalities by inducing α-tubulin polymerization. In BALB/c(nu/nu) mice bearing a HeLa xenograft, CWJ-082 significantly inhibited tumor growth. Taken together, these results suggest that CWJ-082 inhibits cell growth via mitotic arrest by activating the mitotic spindle checkpoint and by inducing α-tubulin polymerization and that these events ultimately lead to the apoptosis of human cervical cancer cells and inhibit tumor growth in HeLa xenograft mice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23615402     DOI: 10.1093/carcin/bgt133

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  3 in total

1.  Isoquinolinamine FX-9 Exhibits Anti-Mitotic Activity in Human and Canine Prostate Carcinoma Cell Lines.

Authors:  Jan Torben Schille; Ingo Nolte; Eva-Maria Packeiser; Laura Wiesner; Jens Ingo Hein; Franziska Weiner; Xiao-Feng Wu; Matthias Beller; Christian Junghanss; Hugo Murua Escobar
Journal:  Int J Mol Sci       Date:  2019-11-07       Impact factor: 5.923

2.  Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.

Authors:  Franziska Weiner; Jan Torben Schille; Jens Ingo Hein; Xiao-Feng Wu; Matthias Beller; Christian Junghanß; Hugo Murua Escobar; Ingo Nolte
Journal:  PLoS One       Date:  2021-08-25       Impact factor: 3.240

3.  Novel chemotherapeutic agent FX-9 activates NF-κB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line.

Authors:  H Murua Escobar; I Nolte; F Weiner; J T Schille; D Koczan; X-F Wu; M Beller; C Junghanss; M Hewicker-Trautwein
Journal:  BMC Cancer       Date:  2021-10-08       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.